Literature DB >> 24088277

Should target organ damage become a therapeutic target?

Vasilios Papademetriou1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24088277      PMCID： PMC8033903          DOI： 10.1111/jch.12184

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  6 in total

Review 1.  Oxidative stress and endothelial dysfunction in hypertension.

Authors:  Eberhard Schulz; Tommaso Gori; Thomas Münzel
Journal:  Hypertens Res       Date:  2011-04-21       Impact factor: 3.872

2.  Endothelial function: a barometer for cardiovascular risk?

Authors:  Joseph A Vita; John F Keaney
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

3.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

Review 4.  The pathogenesis of atherosclerosis: a perspective for the 1990s.

Authors:  R Ross
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

5.  Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients.

Authors:  Pierluigi Costanzo; Gianluigi Savarese; Giuseppe Rosano; Francesca Musella; Laura Casaretti; Enrico Vassallo; Stefania Paolillo; Fabio Marsico; Giuseppe Rengo; Dario Leosco; Pasquale Perrone-Filardi
Journal:  Int J Cardiol       Date:  2012-07-13       Impact factor: 4.164

Review 6.  Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?

Authors:  Gadi Shlomai; Guido Grassi; Ehud Grossman; Giuseppe Mancia
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-08-19       Impact factor: 3.738
  6 in total
  1 in total

Review 1.  Is Left Ventricular Hypertrophy a Valid Therapeutic Target?

Authors:  Jeremy Earl Brooks; Elsayed Z Soliman; Bharathi Upadhya
Journal:  Curr Hypertens Rep       Date:  2019-05-20       Impact factor: 5.369
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.